Nuvalent (NUVL) EBT (2020 - 2026)
Nuvalent's (NUVL) quarterly EBT came in at -$109.1 million in Q1 2026, down 29.24% YoY from -$154.2 million in Q1 2025, and up 7.97% on a QoQ basis from -$118.6 million in Q4 2025.
Nuvalent (NUVL) EBT (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of EBT data on file, last reported at -$109.1 million in Q1 2026.
- Quarterly EBT fell 29.24% year-over-year to -$109.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$449.5 million (down 49.67% YoY) and the FY2025 annual result came in at -$424.8 million, down 63.39% from the prior year.
- EBT grew to -$109.1 million in Q1 2026, from -$118.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$18.6 million in Q1 2022 to a low of -$122.3 million in Q3 2025.
- A 5-year average of -$59.2 million and a median of -$44.1 million in 2024 frame the typical range for EBT.
- The widest YoY moves for EBT: up 32.65% in 2022, down 201.38% in 2022.
- Tracing NUVL's EBT over 5 years: stood at -$27.5 million in 2022, then sank by 39.44% to -$38.3 million in 2023, then tumbled by 94.8% to -$74.6 million in 2024, then plunged by 58.94% to -$118.6 million in 2025, then climbed by 7.97% to -$109.1 million in 2026.
- The last three EBT figures came in at -$109.1 million (Q1 2026), -$118.6 million (Q4 2025), and -$122.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -109.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.11 Mn |
| Dec 31, 2025 | -118.55 Mn |
| Sep 30, 2025 | -122.31 Mn |
| Jun 30, 2025 | -99.51 Mn |
| Mar 31, 2025 | -84.43 Mn |
| Dec 31, 2024 | -74.59 Mn |
| Sep 30, 2024 | -84.31 Mn |
| Jun 30, 2024 | -57.00 Mn |
| Mar 31, 2024 | -44.10 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -27.46 Mn |
| Sep 30, 2022 | -20.58 Mn |
| Jun 30, 2022 | -19.60 Mn |
| Mar 31, 2022 | -18.57 Mn |
| Dec 31, 2021 | -40.78 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |